Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis

1. A compound of formula I,

wherein

X is CHR 1 or CR 1 R 2 , wherein optionally R 1 and R 2 with the C-atom they are bound to form a cycloalkyl or heterocyclyl containing 3 to 7 C-atoms wherein optionally 1 to 3 CH 2 -groups are substituted by —O—, —S—, —SO—, —SO 2 —, —NR′—, —OCO—, —NRCONR′—, —NRCO—, —NRSO 2 R′—, —COO—, —CONR′— or —CH═CH— and wherein optionally 1 to 11 H-atoms are substituted by F or Cl,

D is -E-G-K or -L,

E, K are independently from one another a saturated, unsaturated or aromatic hydrocarboncycle which is unsubstituted or 1 to 4 times substituted by R 1 or R 2 , or a monocylic saturated, unsaturated or aromatic heterocycle with 1 to 4 heteroatoms selected from N, O and S which is unsubstituted or mono-, di- or trisubstituted by R 1 , R 2 , ═S, ═NR 1 or ═O,

G is a single bond,

L is -E-G-K, wherein E and K in addition to the single bond G are linked via an additional alkyl linker containing 1 to 3 C-atoms wherein optionally one CH 2 -group is substituted by —CR 1 R 2 —, —O—, —S—, —SO—, —SO 2 —, —NR 1 —, —OCO—, —NR 1 CONR 2 —, —NR 1 CO—, —NR 1 SO 2 R 2 —, —COO—, —CONR 1 — or —CH═CH—,

Y is H, R 1 or a saturated, unsaturated or aromatic hydrocarboncycle which is unsubstituted or 1 to 4 times substituted by R 1 or a monocylic saturated, unsaturated or aromatic heterocycle with 1 to 4 heteroatoms selected from N, O and S which is unsubstituted or mono-, di- or trisubstituted by R 1 , ═S, ═NR 1 or ═O,

Q is a single bond or a linear, branched or mono- or bicyclic alkyl linker containing 1 to 10 C-atoms wherein optionally 1 to 5 CH 2 -groups are substituted by —CR 3 R 4 —, —S—, —SO—, —SO 2 —, —NR 3 —, —OCO—, —NR 3 CONR 4 —, —NR 3 CO—, —NR 3 SO 2 R 4 ′—, —COO— or —CONR 3 — and wherein optionally 1 to 20 H-atoms are substituted by F or Cl, wherein R 3 and R 4 with the atoms they are bound to optionally form a cycloalkyl or heterocyclyl containing 3 to 7 C-atoms wherein optionally 1 to 3 CH 2 -groups are substituted by —O—, —S—, —SO—, —SO 2 —, —NR—, —OCO—, —NRCONR′— —NRCO—, —NRSO 2 R′—, —COO— or CONR′ and —CH═CH— and wherein optionally 1 to 11 H-atoms are substituted by F or Cl,

R 1 , R 2 , R 3 , R 4 are independently from one another selected from the group consisting of Hal, OR, NRR, SOR, SO 2 R, SO 2 NRR, CN, COOR, CONRR, NRCONRR, NRSO 2 R, NRCOR, a linear or branched alkyl containing 1 to 10 C-atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR, ═O, E, OR, NRR, SOR, SO 2 R, SO 2 NRR, CN, COOR, CONRR, NRCONRR, NRSO 2 R or NRCOR, wherein optionally 1 to 3 CH 2 -groups are substituted by —O—, —S—, —SO—, —SO 2 —, —NR—, —OCO—, —NRCONR′—, —NRCO—, —NRSO 2 R′—, —COO—, —CONR′—, —C≡C— or —CH═CH— and wherein optionally 1 to 20 H-atoms are substituted by F or Cl, and a cycloalkyl or heterocyclyl containing 3 to 7 C-atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR, ═O, E, OR, NRR, SOR, SO 2 R, SO 2 NRR, CN, COOR, CONRR, NRCONRR, NRSO 2 R or NRCOR, wherein optionally 1 to 3 CH 2 -groups are substituted by —O—, —S—, —SO—, —SO 2 —, —NR—, —OCO—, —NRCONR′—, —NRCO—, —NRSO 2 R′—, —COO—, —CONR′— and —CH═CH— and wherein optionally 1 to 11 H-atoms are substituted by F or Cl,

R is H, Hal, R 5 , OR 5 , NR 5 , SO 2 R 5 , SO 2 NR 5 R 6 , CN, COOR 5 , CONR 5 R 6 , NR 5 CONR 5 R 6 , NR 5 SO 2 R 6 , NR 5 COR 6 , a linear or branched alkyl containing 1 to 10 C-atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR 5 , ═O, Hal, E, R 5 , OR 5 , NR 5 , SO 2 R 5 , SO 2 NR 5 R6, CN, COOR 5 , CONR 5 R 6 , NR 5 CONR 5 R 6 , NR 5 SO 2 R 6 or NR 5 COR 6 , wherein optionally 1 to 3 CH 2 -groups are substituted by —O—, —S—, —SO—, —SO 2 —, —NR 5 —, —OCO—, —NR 5 CONR 6 —, —NR 5 CO—, —NR 5 SO 2 R 6 —, —COO—, —CONR 5 —, —C≡C— or —CH═CH— and wherein optionally 1 to 20 H-atoms are substituted by F or Cl, and a cycloalkyl or heterocyclyl containing 3 to 7 C-atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR 5 , ═O, Hal, R 5 , OR 5 , NR 5 , SO 2 R 5 , SO 2 NR 5 R 6 , CN, COOR 5 , CONR 5 R 6 , NR 5 CONR 5 R 6 , NR 5 SO 2 R 6 or NR 5 COR 6 , wherein optionally 1 to 3 CH 2 -groups are substituted by —O—, —S—, —SO—, —SO 2 —, —NR 5 —, —OCO—, —NR 5 CONR 6 —, —NR 5 CO—, —NR 5 SO 2 R 6 —, —COO—, —CONR 5 — or —CH═CH— and wherein optionally 1 to 11 H-atoms are substituted by F or Cl,

R 5 , R 6 independently from one another are H, alkyl or a mono- or bicyclic saturated, unsaturated or aromatic hydrocarboncycle or heterocyle with 1 to 4 heteroatoms selected from N, O and S

R 7 is H or alkyl containing 1 to 7 C-atoms, and

Hal F, Cl, Br or I,

R′ is E, or linear or branched alkylene containing 1 to 10 C-atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR 5 , ═O, Hal, E, R 5 , OR 5 , NR 5 , SO 2 R 5 , SO 2 NR 5 R6, CN, COOR 5 , CONR 5 R 6 , NR 5 CONR 5 R 6 , NR 5 SO 2 R 6 or NR 5 COR 6 , wherein optionally 1 to 3 CH 2 -groups are substituted by —O—, —S—, —SO—, —SO 2 —, —NR 5 —, —OCO—, —NR 5 CONR 6 —, —NR 5 CO—, —NR 5 SO 2 R 6 —, —COO—, —CONR 5 —, —C≡C— or —CH═CH— and wherein optionally 1 to 20 H-atoms are substituted by F or Cl, and a cycloalkyl or heterocyclyl containing 3 to 7 C-atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR 5 , ═O, Hal, R 5 , OR 5 , NR 5 , SO 2 R 5 , SO 2 NR 5 R 6 , CN, COOR 5 , CONR 5 R 6 , NR 5 CONR 5 R 6 , NR 5 SO 2 R 6 or NR 5 COR 6 , wherein optionally 1 to 3 CH 2 -groups are substituted by —O—, —S—, —SO—, —SO 2 —, —NR 5 —, —OCO—, —NR 5 CONR 6 —, —NR 5 CO—, —NR 5 SO 2 R 6 —, —COO—, —CONR 5 — or —CH═CH— and wherein optionally 1 to 11 H-atoms are substituted by F or Cl,

R 4′ is E, or linear branched alkylene containing 1 to 10 C-atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR, ═O, E, OR, NRR, SOR, SO 2 R, SO 2 NRR, CN, COOR, CONRR, NRCONRR, NRSO 2 R or NRCOR, wherein optionally 1 to 3 CH 2 -groups are substituted by —O—, —S—, —SO—, —SO 2 —, —NR′—, —OCO—, —NRCONR′—, —NRCO—, —NRSO 2 R′—, —COO—, —CONR—, —C≡C— or —CH═CH— and wherein optionally 1 to 20 H-atoms are substituted by F or Cl, and a cycloalkyl or heterocyclyl containing 3 to 7 C-atoms which is unsubstituted or mono-, di- or trisubstituted by ═S, ═NR, ═O, E, OR, NRR, SOR, SO 2 R, SO 2 NRR, CN, COOR, CONRR, NRCONRR, NRSO 2 R or NRCOR, wherein optionally 1 to 3 CH 2 -groups are substituted by —O—, —S—, —SO—, —SO 2 —, NR′—, —OCO—,—NRCONR′— —NRCO—, —NRSO 2 R′—, —COO—, —CONR′— and —CH═CH— and wherein optionally 1 to 11 H-atoms are substituted by F or Cl,

or a physiologically acceptable salt, solvate or stereoisomer thereof, including mixtures thereof in all ratios.

2. The compound according to claim 1 in which E is

K is

Q is

or physiologically acceptable salts, solvates or stereoisomers thereof, including mixtures thereof in all ratios.

3. The compound according to claim 1 in which E is

K is

Q is

R 1 ,R 2 are independently from one another a linear or branched alkyl containing 1 to 5 C-atoms which is unsubstituted or mono-, di- or trisubstituted by E, OR, NRR, COOR, CONRR, NRCOR or NRCONRR, wherein optionally 1 to 3 CH 2 -groups are substituted by —O—, —NR′, —OCO—, —NRCONR′—, —NRCO—, —COO— or —CONR′— and wherein optionally 1 to 10 H-atoms are substituted by F, or a cycloalkyl containing 3 to 6 C-atoms which is unsubstituted or mono-, di- or trisubstituted by E, OR, NRR, COOR, CONRR, NRCOR or NRCONRR, wherein optionally 1 to 3 CH 2 -groups are substituted by —O—, —NR′— —OCO—, —NRCONR′—, —NRCO—, —COO— or —CONR′— and wherein optionally 1 to 10 H-atoms are substituted by F,

or physiologically acceptable salts, solvates or stereoisomers thereof, including mixtures thereof in all ratios.

4. The compounds according to claim 1 in which E is

K is

Q is

R 1 ,R 2 are independently from one another methyl, ethyl, propyl, cyclopropyl, isopropyl, butyl, isobutyl, 2-butyl, tert-butyl, cyclobutyl, OH or OR, which is unsubstituted or mono-, di- or trisubstituted by E or OR and wherein optionally 1 to 3 CH 2 -groups are substituted by —O— or —NR— and wherein optionally 1 to 10 H-atoms are substituted by F,

or physiologically acceptable salts, solvates or stereoisomers thereof, including mixtures thereof in all ratios.

5. The compound of formula

a) 4-[(Biphenyl-4-carbonyl)-amino]-2-methyl-4-(3,4,5-trimethoxy-benzylcarbamoyl)-butyric acid

b) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-4-{[5-(4-fluoro-phenyl)-thiazole-2-carbonyl]-amino}-2-methyl-butyric acid

c) (2S,4S)-4-[(Biphenyl-4-carbonyl)-amino]-4-[(S)-2-(4-fluoro-phenyl)-1-methyl-ethylcarbamoyl]-2-methyl-butyric acid

d) (2S,4S)-4-[(Biphenyl-4-carbonyl)-amino]-4-(1,1-dimethyl-2-pyridin-3-yl-ethylcarbamoyl)-2-methyl-butyric acid

e) (2S,4S)-4-[(Biphenyl-4-carbonyl)-amino]-4-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-butyric acid

f) (2S,4S)-2-Benzyl-4-[(biphenyl-4-carbonyl)-amino]-4-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-butyric acid

g) (2S,4S)-2-[(Biphenyl-4-carbonyl)-amino]-2-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-ethyl}-pentanoic acid

h) (2S,4S)-4-[(Biphenyl-4-carbonyl)-amino]-4-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methoxymethyl-butyric acid

i) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-[4-(1-methyl-1H-pyrazol-3-yl)-benzoylamino]-butyric acid

j) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-(4-pyridin-2-yl-benzoylamino)-butyric acid

k) (2S,4S)-4-[(3-Fluoro-biphenyl-4-carbonyl)-amino]-4-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-butyric acid

l) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-4-{[1-(4-fluoro-phenyl)-piperidine-4-carbonyl]-amino}-2-methyl-butyric acid

m) 4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-[(5-phenyl-pyridine-2-carbonyl)-amino]-butyric acid

n) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-[(6-phenyl-pyridine-3-carbonyl)-amino]-butyric acid

o) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-[(4-phenyl-piperazine-1-carbonyl)-amino]-butyric acid

p) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-(4-pyridin-3-yl-benzoylamino)-butyric acid

q) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-[4-(5-methyl-thiazol-2-yl)-benzoylamino]-butyric acid

r) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-4-{[2-(4-fluoro-phenyl)-thiazole-5-carbonyl]-amino}-2-methyl-butyric acid

s) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-(4-pyrazol-1-yl-benzoylamino)-butyric acid

t) (2S,4S)-4-Amino-4-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-butyric acid methyl ester

u) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-[(6-phenyl-pyridine-3-carbonyl)-amino]-butyric acid methyl ester

v) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-(4-pyridin-3-yl-benzoylamino)-butyric acid methyl ester

w) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-(4-pyridin-2-yl-benzoylamino)-butyric acid methyl ester

x) (2S,4S)-4-[(3-Fluoro-biphenyl-4-carbonyl)-amino]-4-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-butyric acid methyl ester

y) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-[4-(1-methyl-1H-pyrazol-3-yl)-benzoylamino]-butyric acid methyl ester

z) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-4-{[5-(4-fluoro-phenyl)-thiazole-2-carbonyl]-amino}-2-methyl-butyric acid methyl ester

aa) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-4-{[2-(4-fluoro-phenyl)-thiazole-5-carbonyl]-amino}-2-methyl-butyric acid methyl ester

bb) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-[4-(5-methyl-thiazol-2-yl)-benzoylamino]-butyric acid methyl ester

cc) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-4-{[1-(4-fluoro-phenyl)-piperidine-4-carbonyl]amino}-2-methyl-butyric acid methyl ester

dd) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-(4-pyrazol-1-yl-benzoylamino)-butyric acid methyl ester

ee) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-[(4-phenyl-piperidine-1-carbonyl)-amino]-butyric acid methyl ester

ff) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-[(4-phenyl-piperazine-1-carbonyl)-amino]-butyric acid methyl ester

gg) (2S,4S)-4-[(Biphenyl-4-carbonyl)-amino]-2-methyl-4-(3,4,5-trimethoxy-benzylcarbamoyl)-butyric acid methyl ester

hh) (2S,4S)-4-[(Biphenyl-4-carbonyl)-amino]-4-[2-(4-fluoro-phenyl)-1-methyl-ethylcarbamoyl]-2-methyl-butyric acid methyl ester

ii) (2S,4S)-4-[(Biphenyl-4-carbonyl)-amino]-4-(1,1-dimethyl-2-pyridin-3-yl-ethylcarbamoyl)-2-methyl-butyric acid methyl ester

jj) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-(4-pyrazin-2-yl-benzoylamino)-butyric acid

kk) (2S,4S)-4-[(Biphenyl-4-carbonyl)-amino]-2-methyl-4-(1,1,3-trimethyl-butylcarbamoyl)-butyric acid

ll) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-[(5-phenyl-pyrazine-2-carbonyl)-amino]-butyric acid

mm) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-(4-pyrazol-1-yl-benzoylamino)-butyric acid

nn) (2S,4S)-4-[4-(1-Difluoromethyl-1H-pyrazol-4-yl)-benzoylamino]-4-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-butyric acid

oo) (2S,4S)-4-[2-(4-Fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2-methyl-4-[4-(1-methyl-1H-pyrazol-3-yl)-benzoylamino]-butyric acid

pp) (S)-4-[(Biphenyl-4-carbonyl)-amino]-4-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethylcarbamoyl]-2,2-dimethyl-butyric acid

qq) (2S,4S)-4-[(Biphenyl-4-carbonyl)-amino]-4-[3-(4-fluoro-benzyl)-oxetan-3-ylcarbamoyl]-2-methyl-butyric acid

rr) (2S,4S)-4-[(Biphenyl-4-carbonyl)-amino]-4-(1,1-dimethyl-propylcarbamoyl)-2-methyl-butyric acid

or physiologically acceptable salts, solvates or stereoisomers thereof, including mixtures thereof in all ratios.

6. The compound according to claim 1 or physiologically acceptable salts, solvates or stereoisomers thereof, including mixtures thereof in all ratios, capable of functioning as ADAMTS5 inhibitors.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to claim 1 or physiologically acceptable salts, solvates or stereoisomers thereof, including mixtures thereof in all ratios.

8. A pharmaceutical composition comprising at least one compound according to claim 1 or physiologically acceptable salts, solvates or stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

9. A process for the preparation of a pharmaceutical composition, comprising bringing a compound according to claim 1 or one of its physiologically acceptable salts, solvates or stereoisomers, including mixtures thereof in all ratios, into a suitable dosage form together with a solid, liquid or semi-liquid excipient or adjuvant.

10. A method for treatment of osteoarthritis, rheumatoid arthritis, traumatic cartilage injuries, pain, allodynia, or hyperalgesia, comprising administering to a host in need thereof an effective amount of a compound according to claim 1 , or a salt or solvate thereof.

11. A kit comprising separate packs of

a) an effective amount of a compound according to claim 1 or physiologically acceptable salts, derivatives, solvates or stereoisomers thereof, including mixtures thereof in all ratios, and

b) an effective amount of a further medicament active ingredient.